Löhn M, Plettenburg O, Kannt A, Kohlmann M, Hofmeister A, Kadereit D, Monecke P, Schiffer A, Schulte A, Ruetten H, Ivashchenko Y. End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899. World J Cardiol 2015; 7(1): 31-42 [PMID: 25632317 DOI: 10.4330/wjc.v7.i1.31]
Corresponding Author of This Article
Dr. Matthias Löhn, Translational Medicine, Sanofi-Aventis, Industriepark Hoechst, 65926 Frankfurt am Main, Germany. matthias.loehn@sanofi.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/